Servier Presents Transformational Data from Pivotal Phase 3

Vorasidenib demonstrated an unprecedented improvement in progression free survival with a median of 27.7 months in patients with residual or recurrent grade 2...

Related Keywords

Boston , Massachusetts , United States , American , Nathan Mellor , Ingok Mellinghoff , Susan Pandya , Ingo Mellinghoff , Prnewswire Servier , Brock Greene , Memorial Sloan Kettering Cancer Center , Servier Pharmaceuticals , European Union , Department Of Neurology , Servier Group , Us Food Drug Administration , Clinical Development , New England Journal , American Society , Clinical Oncology , Memorial Sloan Kettering Cancer , Vice President Clinical Development , Cancer Metabolism Global Development Oncology , Drug Administration , New Drug Application , Central Nervous System ,